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Simultaneous quantitative analysis of olmesartan,
amlodipine and hydrochlorothiazide in their combined dosage 
form utilizing classical and alternating least squares based
chemometric methods
Simultaneous spectrophotometric analysis of a multi-com-
ponent dosage form of olmesartan, amlodipine and hydro-
chlorothiazide used for the treatment of hypertension has 
been carried out using various chemometric methods. Mul-
tivariate calibration methods include classical least squares 
(CLS) executed by net analyte processing (NAP-CLS), or-
thogonal signal correction (OSC-CLS) and direct orthogo-
nal signal correction (DOSC-CLS) in addition to multivari-
ate curve resolution-alternating least squares (MCR-ALS). 
Results demonstrated the effi  ciency of the proposed meth-
ods as quantitative tools of analysis as well as their qualita-
tive capability. The three analytes were determined pre-
cisely using the aforementioned methods in an external 
data set and in a dosage form aft er optimization of experi-
mental conditions. Finally, the effi  ciency of the models was 
validated via comparison with the partial least squares 
(PLS) method in terms of accuracy and precision.
Keywords: multivariate calibration methods, olmesartan 
medoxomil, amlodipine besylate, hydrochlorothiazide, 
spectrophotometry, pharmaceutical tablets
Despite the wideness of spectrophotometric application in pharmaceutical analysis, 
lack of selectivity prevents its application to simultaneous determination of components 
with intensely overlapped absorption bands. Selectivity of spectrophotometric analysis 
can be improved by applying chemometrics (1). In this study, four chemometric methods 
were applied for the quantitative analysis of a ternary mixture of antihypertensive drugs. 
The fi rst method is called multivariate curve resolution-alternating least squares (MCR-
ALS). MCR-ALS has high qualitative properties (providing the pure spectrum of each 
component) but its application to quantitative pharmaceutical analysis is limited (2–6). The 
additional three methods are classical least squares (CLS) preceded by net analyte process-
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ing (NAP-CLS), orthogonal signal correction (OSC-CLS) and direct orthogonal signal cor-
rection (DOSC-CLS). These three pre-processing techniques are applied to improve the 
predictability of the CLS model. This improvement could increase the application of the 
CLS model in quantitative analysis by taking advantage of its inherent qualitative proper-
ties.
The four developed methods were applied to analyze a ternary mixture of olmesartan 
medoxomil (OLM), amlodipine besylate (AML) and hydrochlorothiazide (HCT). Olmesar-
tan medoxomil (Fig. 1) is a powerful and selective angiotensin AT1 receptor blocker (7), 
amlodipine besylate is a calcium channel blocker used for the management of hyperten-
sion and angina pectoris (8) and hydrochlorothiazide is a benzothiadiazine diuretic that 
blocks NaCl transport in distal convoluted tubule (9). This ternary mixture (OLM, AML 
and HCT) is available in the markets as a tablet dosage form (Tribenzor® tablets) in sev-
eral diff erent dosages. Few methods are available for simultaneous analysis of this ternary 
mixture. According to extensive literature review, the reported methods for analysis of 
this mixture include high performance liquid chromatography (HPLC) (10–12), spectro-
photometry (13–16) and chemometric methods (16, 17). Chemometric methods that were 
used for spectrophotometric data in previous work were CLS, PCR and partial least 
squares (PLS) (17) and artifi cial neural network (ANN) (16). In the work of Darwish et al. 
(17) on the same drug mixture the predictability of CLS method was found to be low. This 
fi nding motivated us to further extend our work and to investigate the quantitative power 
of other methods as compared to PLS.
FDA approved Tribenzor® tablets in four ratios. All the reported methods were devel-
oped for the analysis of only one ratio for this combination (4:1:2.5). Hence, this study was 
designed to achieve a number of goals. Firstly, to develop simple, robust and accurate 
chemometric methods for the simultaneous determination of OLM, AML and HCT in 
Tribenzor® tablets in all FDA approved ratios; secondly, to show the quantitative power as 
well as qualitative power of the proposed methods. Thirdly, to show the eff ect of diff erent 
preprocessing procedures, such as NAP, OSC and DOSC, on the performance of CLS in 
quantitative analysis, since other chemometric approaches designed only for quantitative 
analysis [e.g., multiple linear regression (MLR) and locally weighted regression (LWR) 
were not applied in this study].
Fig. 1. Chemical structures of olmesartan medoxomil (OLM), amlodipine besylate (AML) and hydro-
chlorothiazide (HCT).
               Olmesartan medoxomil (OML)                   Amlodipine besylate (AML)       Hydrochlorothiazide (HCT)
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A double-beam UV-visible spectrophotometer (Shimadzu, Japan) model UV-1650 PC, 
with a quartz cuvett e cell of 1-cm path length, was connected to an IBM-compatible com-
puter. The spectral bandwidth was 2 nm and wavelength-scanning speed 2800 nm min–1. 
A UV lamp with a short wavelength (254 nm) was used. All recorded spectra were con-
verted to the ASCII format by the UV-probe personal spectroscopy soft ware version 2.21 
(Shimadzu).
Materials
OLM was acquired from AK Scientifi c Inc. (USA), HCT from Al-Hekma Pharmaceuti-
cal Company (Egypt) and AML was kindly supplied by Pfi zer Inc. (USA). The purities of 
OLM, AML and HCT were 99.5, 99.5 and 99.78 %, respectively. Tribenzor® tablet is avail-
able in several diff erent strength combinations including, 40/10/25 mg, 40/10/12.5 mg, 
40/5/25 mg and 40/5/12.5 mg of OLM, AML base (10 mg or 5 mg of AML base equivalent to 
13.9 mg or 6.95 mg of AML besylate) and HCT, respectively. Tribenzor® tablets were pro-
cured from Daiichi Sankyo Inc., USA). Acetonitrile used throughout this study was of 
spectroscopic grade (Sigma-Aldrich Chemie GmbH, Germany).
Preparation of OLM, AML and HCT standard solutions
Stock solutions of OLM (250 μg mL−1), AML (200 μg mL−1) and HCT (250 μg mL−1) were 
prepared in acetonitrile. All stock solutions were stored at 4 °C until analysis.
Preparation of pharmaceutical tablet sample solutions
Seven tablets of each Tribenzor® formulation were weighed and the average tablet 
mass was calculated. Tablets were crushed to a fi ne powder, and a quantity of powdered 
tablets, equivalent to the mass of one tablet was extracted with 80 mL acetonitrile with the 
help of sonication for 30 min and diluted up to 100 mL with acetonitrile. The extracts were 
fi ltered through a 0.45-μm MF-Millipore membrane fi lter (composed of mixed cellulose 
esters) and the fi rst portion of each  fi ltrate was discarded. The filtrates were then diluted 
with the same solvent and subjected to analysis by the developed method.
Chemometric procedures and soft wares
Principles and theoretical background of the chemometric methods are detailed in the 
literature for the MCR-ALS method (2, 18, 19), CLS model (20) and diff erent pre-processing 
techniques (NAP, OSC and DOSC) (21–25).
MCR-ALS, NAP-CLS and OSC-CLS methods were implemented in Matlab® 7.1.0.246 
(R14) using MCR-ALS (26) and MVC1 toolboxes (27).
Multi-level, multi-factor calibration design (28) was used for construction of 25 mix-
ture samples by transferring diff erent volumes of OLM, AML and HCT from their stan-
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dard stock solutions into 5-mL measuring fl asks. Dilution of these solutions was done with 
acetonitrile and mixed well (Table I). Fift een of the above-mentioned 25 samples were used 
to construct chemometric models (calibration set) and 10 samples were used as a validation 
set to test the predictive power of the developed models. For the diff erent ratios of three 
analytes in Tribenzor® tablets, each analyte concentration range was dependent on the 
Table I. The 5-level 3-factor experimental design of the calibration and validation set mixturesa
Mix OLM AML HCT Mix OLM AML HCT
1 20.00 5 12.50 14 20.00 7 15.00
2 20.00 3 10.00 15 25.00 7 10.00
3 15.00 3 15.00 16 25.00 3 13.75
4 15.00 7 11.25 17 15.00 6 10.00
5 25.00 4 15.00 18 22.50 3 12.50
6 17.50 7 12.50 19 15.00 5 13.75
7 25.00 5 11.25 20 20.00 6 13.75
8 20.00 4 11.25 21 22.50 6 11.25
9 17.50 4 13.75 22 22.50 4 10.00
10 17.50 6 15.00 23 17.50 3 11.25
11 22.50 7 13.75 24 15.00 4 12.50
12 25.00 6 12.50 25 17.50 5 10.00
13 22.50 5 15.00
a Concentrations of mixture components in μg mL–1.
Fig. 2. Absorption spectra for OLM, AML and HCT against acetonitrile as a blank (10 μg mL–1 each).
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calibration range of each analyte in 25 samples. UV spectra of all the 25 samples were ob-
tained from 200 to 400 nm against solvent blank and subject to Matlab for calculations. The 
noisy region (200–230 nm) and the zero absorbance of OLM and HCT aft er 340 nm ex-
plained the rejection of these parts from the spectra (Fig. 2).
A plot of the 2D scores for the fi rst two PCs of the concentration matrix confi rmed the 
position of the samples in space, orthogonality, rotatability and symmetry (28) as antici-
pated in Fig. 3. Mean centering of the data showed to be the best pre-processing procedure 
for gett ing the best results in case of improved CLS methods.
Optimization of the number of factors for the NAP-CLS, OSC-CLS and DOSC CLS models. 
– Leave-one-out (LOO) CV was used in our study for optimizing the number of factors for 
building the investigated methods (20), by building the model using the I-1 sample set 
(calibration set consisting of 14 samples) to predict the one sample left  (validation sample). 















where I is the number of objects in the calibration set, ci is the known concentration for 
sample i and Ai_cvĉ  is the predicted concentration of sample i using A components. Mean 
centering was applied on the calibration set each time successive samples were left  out.
Root mean square of calibration (RMSEC), root mean square of prediction (RMSEP) 
were calculated in the same manner for the calibration and validation set, respectively, 















Fig. 3. Score plot for the mean centred 25 samples concentration matrix of the fi ve level three compo-
nent experimental design. PC 1, 2 – fi rst, second principal component.
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where I is the number of samples in the calibration (in case of RMSEC) or validation set (in 
case of RMSEP), ci is the known concentration for sample i and 
A
iĉ  is the estimated concen-
tration of sample i using A components. RMSEC gives an idea about the quality of the 
developed models while RMSEP shows the prediction power of the developed models.
RESULTS AND DISCUSSION
MCR-ALS method
MCR-ALS method is supposed to provide an ideal estimation of the concentration and 
spectra profi les of the three analytes OLM, AML and HCT. First, the model was applied 
on the calibration set (15 samples). Non-negativity constraint was applied for both concen-
tration and spectral data. The pronounced resemblance between the estimated pure spec-
tra of OLM, AML and HCT and the true ones (Fig. 4) assured the performance of the 
model to predict pure spectra for the three components in the analyzed mixture. Evolving 
factor analysis (EFA) was used to predict the concentration profi les of the three compo-
nents.
Values of the lack of fi tness (lof), percent of variance and standard deviation of the 
residuals with respect to the experimental data were 0.10889, 99.999 % and 0.00089, respec-
tively, at iteration number 13. These values indicate the high quality of the model.
Improved CLS models
For proper construction of NAP-CLS, OSC-CLS and DOSC-CLS models, the number 
of projection matrix factors (NAP-CLS) and the number of extracted factors (OSC-CLS and 
DOSC-CLS) should be optimized. For this reason, CV was applied where log PRESS (pre-
dicted residual error sum of squares) values were calculated. The optimal number of fac-
Fig. 4. Estimated absorption spectra by: a) MCR-ALS and b) true spectra, of OLM, AML and HCT 
against acetonitrile.
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Table II. Prediction of the calibration set by MCR-ALS and improved-CLS methods
Method MCR-ALS NAP-CLS
OLM AML HCT OLM AML HCT OLM AML HCT
True (μg mL–1) Recovery (%) Recovery (%) Recovery (%) Recovery (%) Recovery (%) Recovery (%)
25 7 10 98.92 99.29 99.40 99.32 99.14 100.20
15 3 15 98.27 100.00 99.27 98.33 100.00 99.20
15 4 12.5 99.20 101.25 100.72 98.67 101.25 100.24
15 5 13.75 100.13 99.20 100.58 99.93 99.20 100.65
15 6 10 100.67 99.17 99.80 99.47 99.17 98.70
15 7 11.25 100.13 99.71 100.36 99.33 99.57 99.91
17.5 3 11.25 100.97 101.67 101.16 100.69 101.67 100.44
17.5 7 12.5 100.91 100.57 101.28 100.97 100.71 101.68
17.5 4 13.75 101.89 99.25 100.51 102.17 99.25 100.73
17.5 5 10 101.83 102.40 101.30 101.31 102.20 100.50
17.5 6 15 99.60 98.00 99.87 100.11 98.17 100.53
20 5 12.5 99.70 94.40 98.08 100.00 94.40 98.32
20 3 10 99.65 99.33 100.80 99.45 99.33 99.90
20 4 11.25 101.10 101.00 100.44 101.20 100.75 100.27















RMSEC (g mL–1) 0.2026 0.1227 0.1270 0.1863 0.1220 0.1107
OSC-CLS DOSC-CLS
OLM AML HCT OLM AML HCT OLM AML HCT
True (μg mL–1) Recovery (%) Recovery (%) Recovery (%) Recovery (%) Recovery (%) Recovery (%)
25 7 10 99.40 99.43 100.20 99.40 99.43 100.20
15 3 15 98.20 99.67 99.20 98.20 100.00 99.27
15 4 12.5 98.60 101.00 100.24 98.60 101.00 100.24
15 5 13.75 100.00 99.20 100.51 100.00 99.20 100.58
15 6 10 99.60 99.00 98.60 99.53 99.00 98.60
15 7 11.25 99.53 99.57 99.73 99.53 99.57 99.82
17.5 3 11.25 100.46 101.67 100.62 100.51 101.67 100.53
17.5 7 12.5 101.20 100.71 101.60 101.20 100.71 101.60
17.5 4 13.75 102.11 99.250 100.73 102.11 99.25 100.73
17.5 5 10 101.26 102.20 100.50 101.26 102.20 100.50
17.5 6 15 100.29 98.17 100.40 100.23 98.17 100.53
20 5 12.5 99.95 94.40 98.32 99.95 94.40 98.32
20 3 10 99.20 99.33 100.20 99.25 99.33 100.10
20 4 11.25 101.10 101.00 100.44 101.10 101.00 100.36















RMSEC (g mL–1) 0.1842 0.1235 0.1111 0.1848 0.1235 0.1097
RMSEC – root mean square error of calibration.
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tors was selected according to Haaland and Thomas (29). Two factors were required for 
building improved CLS models for the three analytes except in the case of OSC-CLS for 
HCT where three factors were required. This fact shows that NAP, as a pre-processing 
technique, is simpler than OSC, especially in the case of HCT, even when the prediction 
ability of the CLS model is not enhanced.
Aft er parameters optimization and the calibration step, all models were applied suc-
cessfully for estimation of OLM, AML and HCT in calibration (Table II) and in validation 
Table III. Prediction of the independent validation test set by the proposed MCR-ALS and improved CLS 
methods
MCR-ALS NAP-CLS
OLM AML HCT OLM AML HCT OLM AML HCT
True (μg mL–1) Recovery (%) Recovery (%) Recovery (%) Recovery (%) Recovery (%) Recovery (%)
20 7 15 100.75 99.86 99.00 101.60 100.00 100.07
22.5 3 12.5 100.40 100.67 102.08 101.07 100.67 102.56
22.5 4 10 101.16 102.50 100.40 101.38 102.25 100.30
22.5 5 15 100.62 99.00 98.73 101.64 99.20 99.80
22.5 6 11.25 99.64 99.00 97.42 100.00 99.00 97.87
22.5 7 13.75 100.93 99.57 94.91 101.69 99.71 96.00
25 3 13.75 100.16 95.33 98.98 101.16 95.33 99.85
25 4 15 99.88 96.00 96.20 101.04 96.25 97.40
25 5 11.25 99.36 97.60 97.07 99.96 97.40 97.60















RMSEP (g mL–1) 0.1594 0.1064 0.3428 0.2627 0.1027 0.2771
OSC-CLS DOSC-CLS
OLM AML HCT OLM AML HCT OLM AML HCT
True (μg mL–1) Recovery (%) Recovery (%) Recovery (%) Recovery (%) Recovery (%) Recovery (%)
20 7 15 101.85 100.00 100.00 101.80 100.00 100.07
22.5 3 12.5 100.89 101.00 102.72 100.93 101.00 102.64
22.5 4 10 101.24 102.50 100.50 101.24 102.50 100.30
22.5 5 15 101.69 99.20 99.80 101.69 99.20 99.87
22.5 6 11.25 100.00 99.17 97.96 100.00 99.17 97.87
22.5 7 13.75 101.87 99.71 95.93 101.82 99.71 96.00
25 3 13.75 101.00 96.00 100.07 101.04 95.67 99.93
25 4 15 100.96 96.50 97.47 100.96 96.50 97.47
25 5 11.25 99.88 97.80 97.87 99.88 97.80 97.69















RMSEP (g mL–1) 0.2641 0.0950 0.2776 0.2627 0.0963 0.2768
RMSEP – root mean square error of prediction.
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sets (Table III). The mean recovery, standard deviation, RMSEC, RMSEP values are sum-
marized in Tables II and III. The law values of RMSEP indicate the minor error of predic-
tion and the high predictive ability of the developed methods.
The suggested methods were then applied with a great success to the analysis of 
Tribenzor® tablets in all FDA approved ratios (Table IV). This fact was further assessed by 
the statistical comparison of t- and F-values of the suggested models and the reference PLS 
method (17) (Table V), showing that there was no signifi cant diff erence between our mod-
els and the reference in either accuracy or precision.
Figures of merit
Figures of merit were calculated by the MVC1 toolbox for NAP-CLS, OSC-CLS and 
DOSC-CLS models. The results for the suggested models for the three drugs are presented 
in Table VI. The best fi gures of merit were obtained from the application of the DOSC-CLS 
model. This is indicated by the high sensitivity and selectivity and low values of LOD. This 
may be att ributed to the highest capability of DOSC-CLS to extract the noise from the 
spectral data.
Table IV. Analysis results for the prediction of the dosage form by the proposed MCR-ALS and improved-CLS 
methods
Dosage form MCR-ALS NAP-CLS
Ratio Label claim (μg mL–1) OLM AML HCT OLM AML HCT
OLM AML HCT OLM AML HCT % of the label claim
4 1 2.5 20 6.95 12.5 97.48 98.48 97.79 97.53 98.68 98.04
4 1 1.25 30 10.42 9.375 102.61 97.75 96.42 103.41 101.54 98.60
8 1 5 30 5.21 18.75 101.73 98.11 99.87 103.77 96.73 102.22
8 1 2.5 30 5.21 9.375 101.34 96.09 99.59 102.14 98.85 100.69
Mean (%) 100.79 97.61 98.42 101.72 98.95 99.89
SD 2.27 1.06 1.62 2.88 1.98 1.93
Dosage form OSC-CLS DOSC-CLS
Ratio Label claim (μg mL–1) OLM AML HCT OLM AML HCT
OLM AML HCT OLM AML HCT % of the label claim
4 1 2.5 20 6.95 12.5 97.43 98.01 97.97 97.39 98.48 97.86
4 1 1.25 30 10.42 9.375 102.07 98.91 98.63 102.09 98.71 98.6
8 1 5 30 5.21 18.75 103.63 96.48 102.24 103.62 96.38 102.29
8 1 2.5 30 5.21 9.375 103.84 98.58 101.19 103.83 98.58 100.69
Mean (%) 101.74 98.00 100.01 101.73 98.04 99.86
SD 2.98 1.08 2.04 3.00 1.11 2.02
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Our work provides the fi rst spectrophotometric method designed for the analysis of 
Tribenzor tablets in all FDA approved ratios. In addition, other reported spectrophotomet-
ric methods (13–15) experienced low robustness since they are considered as univariate 
calibration methods (calibration relies on measuring absorbances at just one wavelength). 
Thus, any error in the wavelength scale will prompt false results. Incorporation of numer-
ous spectral wavelengths instead of utilizing a solitary wavelength enhances enormously 
the precision and predictive power of the multivariate calibration methods.
Table V. Statistical comparison of the results obtained by MCR-ALS and improved CLS methods and the 
reference PLS method for the analysis of Tribenzor® tablets
Parameter
MCR-ALS NAP-CLS Reference method (ref. 17)
OLM AML HCT OLM AML HCT OLM AML HCT
% of
label claim 
97.48 98.48 97.79 97.53 98.68 98.04 103.48 97.6 98.6
102.61 97.75 96.42 103.41 101.54 98.60 103.66 98.86 102.23
101.73 98.11 99.87 103.77 96.73 102.22 101.88 96.51 101.09
101.34 96.09 99.59 102.14 98.85 100.69 97.29 97.38 97.94
Mean (%) 100.79 97.61 98.42 101.72 98.95 99.89 101.58 97.59 99.97
SD 2.270 1.055 1.619 2.877 1.976 1.928 2.968 0.97 2.03
Variance 5.153 1.113 2.621 8.277 3.905 3.718 8.809 0.941 4.121
Number of 
samples 4 4 4 4 4 4 4 4 4
Student’s ta 0.422 0.028 1.192 0.067 1.238 0.055 – – –
F ratioa 1.710 1.182 1.192 1.064 4.151 1.108 – – –
OSC-CLS DOSC-CLS Reference method (ref. 17)
OLM AML HCT OLM AML HCT OLM AML HCT
% of
label claim
102.07 98.01 97.97 97.39 98.48 97.86 103.48 97.60 98.60
97.428 98.91 98.63 102.09 98.71 98.60 103.66 98.86 102.23
103.63 96.48 102.24 103.62 96.38 102.29 101.88 96.51 101.09
103.84 98.58 101.19 103.83 98.58 100.69 97.29 97.38 97.94
Mean (%) 101.74 98.00 100.01 101.73 98.04 99.86 101.58 97.59 99.97
SD 2.982 1.076 2.036 2.997 1.109 2.015 2.968 0.97 2.03
Variance 8.895 1.158 4.144 8.982 1.230 4.060 8.809 0.941 4.121
Number of 
samples 4 4 4 4 4 4 4 4 4
Student’s ta 0.078 0.562 0. 030 0.073 0.611 0.070 – – –
F ratioa 1.01 1.231 1.006 1.02 1.307 1.015 – – –
a For p = 0.05 and 6 degrees of freedom tabular cries t and F are 2.447 and 9.277, respectively.
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CONCLUSIONS
Diff erent chemometric models have been applied for the analysis of OLM, AML and 
HCT in their combined dosage form. The methods are: MCR-ALS, NAP-CLS, OSC-CLS and 
DOSC-CLS methods. These methods have the qualitative power (estimation of pure spec-
tra) as well as quantitative power (prediction of concentrations of the three analytes in 
their mixtures). The developed methods are more rapid and easier compared to the tradi-
tional spectrometric methods along with other important analytical merits such as sensi-
tivity and selectivity. Among the proposed pre-processing steps, DOSC was the most pow-
erful one, increasing the quantitative power of the CLS method. All the suggested methods 
were validated and can be applied for routine quality control analysis of Tribenzor® tablets 
in all FDA approved ratios without prior separation or interference from commonly en-
countered additives.
Acronyms. – AML – amlodipine besylate, ANN – artifi cial neural network, CLS – classical least 
squares, DOSC – direct orthogonal signal correction, HCT – hydrochlorothiazide, LWR – locally 
weighted regression, MCR-ALS – multivariate curve resolution-alternating least squares, MLR – mul-
tiple linear regression, NAP – net analyte processing, OLM – olmesartan medoxomil, OSC – or-
thogonal signal correction, PCR – principal component regression, PLS – partial least squares.
Table VI. Figures of merit of OLM, AML and HCT for improved CLS methods
Component Figure of merit NAP-CLS OSC-CLS DOSC-CLS
OLM Sensitivity (mL g–1)a 0.089 0.091 0.22
Analytical sensitivity (mL g–1)b 78 80 190
Selectivityc 0.4 0.41 1
LOD (g mL–1)d 0.037 0.036 0.015
AML Sensitivity (mL g–1)a 0.074 0.074 0.2
Analytical sensitivity (mL g–1)b 65 65 180
Selectivityc 0.36 0.37 0.99
LOD (g mL–1)d 0.045 0.045 0.017
HCT Sensitivity (mL g–1)a 0.15 0.15 0.19
Analytical sensitivity (mL g–1)b 130 130 170
Selectivityc 0.79 0.8 1
LOD (g mL–1)d 0.022 0.022 0.017
All the methods were built by 2 factors except OSC-CLS model, which was built by 3 factors for HCT.
a Calibration sensitivity measures the changes in response as a function of the concentration of a particular analyte.
b Analytical sensitivity equals sensitivity divided by instrumental noise.
c Selectivity indicates the part of the total signal that is not lost due to spectral overlap.
d Limit of detection is the lowest concentration of an analyte that can be detected, but not necessarily quantifi ed.
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